James Wan Is aware of You are Dying for Particulars About That R-Rated ‘M3GAN’ Sexbot Spin-Off

Everybody’s favourite kill-crazy toy not named Chucky is again in theaters June 27, and if M3GAN 2.0 captures audiences just like the 2023 unique did, a 3rd movie appears all however assured. However earlier than a trilogy would possibly occur, one other movie in M3GAN’s universe will arrive: SOULM8TE, the beforehand introduced R-rated spin-off that can look at the hazards of AI from a extra grown-up perspective.

In new interviews, producer James Wan and M3GAN star Allison Williams (an government producer on SOULM8TE) spilled a couple of beans on what to anticipate.

Each Wan and Williams advised Entertainment Weekly that SOULM8TE got here from the inevitable questions raised by a world with the means to create an eerily lifelike AI doll.

“We will provide you with a special individual and a special story and an R-rated world to do that in. Let M3GAN be M3GAN, and depart her out of this utterly,” Williams mentioned. “It felt irresistible to then say, if a M3GAN existed in our world, somebody would take that tech and put it within the type of a female-bodied individual whose sole function on the planet is to pleasure an individual. We extrapolate from there.”

Wan mentioned SOULM8TE is “mainly set in the identical AI world however seen by way of a extra grown-up perspective, one which embraces all the nice erotic thrillers from the ’90s. It’s like Deadly Attraction however with robots.” There can be humor baked in, however not on the extent of “sassiness” as what the M3GAN movies deliver to the desk.

Search for SOULM8TE—directed by Kate Dolan (You Are Not My Mom) and starring Evil Lifeless Rise‘s Lily Sullivan because the terrifying AI companion—to boost theaters January 2, 2026.

Need extra io9 information? Try when to count on the most recent Marvel, Star Wars, and Star Trek releases, what’s subsequent for the DC Universe on film and TV, and all the things it’s essential to find out about the way forward for Doctor Who.